Cargando…
Suicide and Antidepressants: What Current Evidence Indicates
The documented efficacy and long-term benefit of antidepressants in patients with recurrent forms of severe anxiety or depressive disorders support their use in those individuals with these disorders, who experience suicidal thoughts or behavior. In general, it is assumed that antidepressants are be...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3353604/ https://www.ncbi.nlm.nih.gov/pubmed/22654381 http://dx.doi.org/10.4103/0973-1229.87287 |
_version_ | 1782233075834421248 |
---|---|
author | Nischal, Anil Tripathi, Adarsh Nischal, Anuradha Trivedi, J. K. |
author_facet | Nischal, Anil Tripathi, Adarsh Nischal, Anuradha Trivedi, J. K. |
author_sort | Nischal, Anil |
collection | PubMed |
description | The documented efficacy and long-term benefit of antidepressants in patients with recurrent forms of severe anxiety or depressive disorders support their use in those individuals with these disorders, who experience suicidal thoughts or behavior. In general, it is assumed that antidepressants are beneficial for all symptoms of depression, including suicidality. However, some evidence suggests that Selective Serotonin Reuptake Inhibitors [SSRIs] may cause worsening of suicidal ideas in vulnerable patients. Systematic reviews and pooled analysis of experimental, observational, and epidemiological studies have investigated the use of SSRIs and their association with suicidality. Taking account of the methodological limitations of these studies, the current evidence fails to provide a clear relationship between their use and risk of suicidality in adults. However, in children and adolescents, there appears to be a bit of increased risk of suicidal ideations and attempts, but not of completed suicides. This risk can be anticipated and managed clinically. Clinicians are, therefore, advised to maintain a close follow-up during the initial treatment periods and remain vigilant of this risk. This advisory, however, should not deter clinicians from the use of effective dosages of antidepressants for a sufficient period of time, in every age group of patients, when clinically needed, and if found suitable otherwise. |
format | Online Article Text |
id | pubmed-3353604 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Medknow Publications & Media Pvt Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-33536042012-05-31 Suicide and Antidepressants: What Current Evidence Indicates Nischal, Anil Tripathi, Adarsh Nischal, Anuradha Trivedi, J. K. Mens Sana Monogr Review Article The documented efficacy and long-term benefit of antidepressants in patients with recurrent forms of severe anxiety or depressive disorders support their use in those individuals with these disorders, who experience suicidal thoughts or behavior. In general, it is assumed that antidepressants are beneficial for all symptoms of depression, including suicidality. However, some evidence suggests that Selective Serotonin Reuptake Inhibitors [SSRIs] may cause worsening of suicidal ideas in vulnerable patients. Systematic reviews and pooled analysis of experimental, observational, and epidemiological studies have investigated the use of SSRIs and their association with suicidality. Taking account of the methodological limitations of these studies, the current evidence fails to provide a clear relationship between their use and risk of suicidality in adults. However, in children and adolescents, there appears to be a bit of increased risk of suicidal ideations and attempts, but not of completed suicides. This risk can be anticipated and managed clinically. Clinicians are, therefore, advised to maintain a close follow-up during the initial treatment periods and remain vigilant of this risk. This advisory, however, should not deter clinicians from the use of effective dosages of antidepressants for a sufficient period of time, in every age group of patients, when clinically needed, and if found suitable otherwise. Medknow Publications & Media Pvt Ltd 2012 /pmc/articles/PMC3353604/ /pubmed/22654381 http://dx.doi.org/10.4103/0973-1229.87287 Text en Copyright: © Mens Sana Monographs http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Nischal, Anil Tripathi, Adarsh Nischal, Anuradha Trivedi, J. K. Suicide and Antidepressants: What Current Evidence Indicates |
title | Suicide and Antidepressants: What Current Evidence Indicates |
title_full | Suicide and Antidepressants: What Current Evidence Indicates |
title_fullStr | Suicide and Antidepressants: What Current Evidence Indicates |
title_full_unstemmed | Suicide and Antidepressants: What Current Evidence Indicates |
title_short | Suicide and Antidepressants: What Current Evidence Indicates |
title_sort | suicide and antidepressants: what current evidence indicates |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3353604/ https://www.ncbi.nlm.nih.gov/pubmed/22654381 http://dx.doi.org/10.4103/0973-1229.87287 |
work_keys_str_mv | AT nischalanil suicideandantidepressantswhatcurrentevidenceindicates AT tripathiadarsh suicideandantidepressantswhatcurrentevidenceindicates AT nischalanuradha suicideandantidepressantswhatcurrentevidenceindicates AT trivedijk suicideandantidepressantswhatcurrentevidenceindicates |